{
  "trial_id": "NCT00968240",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA)",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Karnofsky performance status greater or equal to 60%",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "expected survival of greater or equal to three months",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "male or female patients of greater or equal 18 years of age",
      "label": "met",
      "evidence": "patient text"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients previously treated with more than 6 cycles (28 days each) of Bevacizumab at 10/mg/kg",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Women who are pregnant or lactating",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of anaplastic astrocytoma and is being treated with Avastin. They meet several inclusion criteria, but have not been previously treated with Bevacizumab.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT00968240",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}